For all 3 co-primary end points , the sarilumab 150 mg and 200 mg groups demonstrated statistically significant improvements as compared with the placebo group ( ACR20 response rate at week 24 , 58.0 % , 66.4 % , and 33.4 % , respectively [ P < 0.0001 ] ; least squares mean change in HAQ DI at week 16 , -0.53 , -0.55 , and -0.29 , respectively [ P < 0.0001 ] ; and mean change in SHS at week 52 , 0.90 , 0.25 , and 2.78 , respectively [ P < 0.0001 ] ) .